FHD-286 in Subjects With Advanced Hematologic Malignancies
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the
safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical
activity of FHD-286 oral monotherapy in subjects with advanced hematologic malignancies,
specifically relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R myelodysplastic
syndromes (MDS).